Press release
Pharma M&A Deals Market is Set to Experience a Revolutionary Growth
Pharma M&A Deals
The Pharma M&A Deals Market in Q2 2025 reflects a strong resurgence in strategic acquisitions, driven by patent cliffs, portfolio expansion needs, rising biologics competition, and increased investor confidence in biotech innovation. Total disclosed deal value reached USD 152 billion in Q2 2025, marking a significant acceleration compared to the previous quarter.
Large pharmaceutical companies are aggressively acquiring biotech firms with assets in oncology, neurology, immunology, rare diseases, and cell & gene therapy, aiming to secure long-term revenue streams. Meanwhile, mid-size biotechs continue to seek partnerships, licensing, and acquisition exits due to higher R&D expenditure and financing challenges.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73660
The strong deal environment across the quarter underscores the sector's pivot toward precision therapies, advanced modalities, and late-stage clinical assets.
Key Drivers of Pharma M&A in Q2 2025
• Upcoming Patent Expiries: Major pharma companies face revenue risks from blockbuster drug expirations and are acquiring innovative pipelines to offset declines.
• Biotech Financing Gaps: Many small biotechs seek acquisition partners as public and venture funding tightens.
• Strong Appetite for Advanced Modalities: High interest in cell therapy, gene therapy, radiopharmaceuticals, ADCs, and mRNA platforms.
• R&D Consolidation: Strategic acquisitions aimed at strengthening late-stage clinical pipelines.
• AI-Driven Drug Discovery Demand: Pharma companies acquire AI and platform-biotech firms to accelerate drug development timelines.
• Growth in Specialty & Rare-Disease Markets: M&A focuses on orphan drugs, high-value biologics, and breakthrough therapies.
• Shift Toward Precision Medicine: Enhanced focus on targeting smaller but high-value patient populations.
Market Challenges
• High Valuation Expectations: Many biotech firms still demand premium valuations despite lower earnings.
• Integration Risks: Cultural and operational differences create post-acquisition challenges.
• Regulatory Scrutiny: Competition authorities closely monitor large-scale M&A to prevent monopolistic behavior.
• Clinical Uncertainty: Acquiring early-stage assets carries failure risk in Phase II/III trials.
• Manufacturing Complexity: Advanced therapies require specialized facilities and integration into existing supply chains.
Market Segmentation
By Deal Type
• Full Acquisitions
• Majority Stake Acquisitions
• Joint Ventures
• Licensing Agreements
• R&D Collaborations
• Divestitures
By Therapeutic Focus
• Oncology
• Neurology
• Immunology
• Rare Diseases
• Cardiovascular & Metabolic Diseases
• Infectious Diseases
• Cell & Gene Therapy
• Vaccines
By Company Size
• Large Multinational Pharma
• Mid-Tier Biopharma
• Emerging Biotech
• Technology & AI-Drug Discovery Firms
By Geography
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/73660/pharma-m-a-deals-q2-2025-market
Q2 2025 Regional Insights
North America
North America dominated Q2 2025 pharma M&A with over 55% of total deal value, driven by the presence of major pharma headquarters, abundant biotech targets, and robust capital markets.
Europe
Europe saw strong cross-border acquisition activity, particularly in oncology and rare diseases. Several mid-size European biotechs were acquired by U.S. pharma companies expanding their global pipelines.
Asia Pacific
Asia Pacific continues to gain momentum with increased investments in biosimilars, vaccines, and biologics manufacturing. Japan, China, and South Korea were key contributors.
Latin America
Growth was modest, driven mostly by strategic portfolio expansions in generics and biosimilars.
Middle East & Africa
Early-stage investments and collaborations increased, especially in clinical trial expansion and vaccine partnerships.
Competitive Landscape - Major Companies Engaged in Q2 2025 M&A
1. Pfizer
2. Johnson & Johnson
3. Merck & Co.
4. Eli Lilly
5. Novartis
6. Roche
7. AstraZeneca
8. Bristol-Myers Squibb
9. Sanofi
10. AbbVie
11. Takeda
12. Bayer
13. Amgen
14. GSK
15. Regeneron
16. Biogen
17. Moderna
18. Gilead Sciences
19. Vertex Pharmaceuticals
20. Leading emerging biotech companies across oncology and gene therapy
These companies pursued acquisition targets such as late-stage oncology assets, neurology drug candidates, platform technologies, AI discovery engines, and next-generation biologics.
Notable Deal Trends in Q2 2025
• Increased oncology-focused acquisitions, especially for antibody-drug conjugates (ADCs) and immunotherapies.
• Strong gene therapy interest, with multiple acquisitions of companies developing AAV and non-viral genomic technologies.
• Radiopharmaceutical M&A momentum, driven by success in targeted cancer therapies.
• AI biotech acquisitions, as pharma integrates machine learning into discovery pipelines.
• Strengthening rare-disease portfolios, particularly in neuromuscular and metabolic disorders.
• More strategic divestitures as pharma companies streamline non-core operations.
Opportunities Ahead
• Expansion of precision oncology and biomarker-driven drug programs.
• Rising interest in hybrid M&A models, combining equity investment with R&D collaboration.
• Potential for mega-mergers as companies seek long-term revenue stability.
• Growing M&A activity in biosimilar developers as biologics patents expire.
• Increasing valuation of companies with validated RNA, cell therapy, and genome editing platforms.
• High appetite for AI drug discovery companies, offering speed and efficiency advantages.
Conclusion
The Pharma M&A Deals Market in Q2 2025 shows a strong comeback, with total deal value reaching USD 152 billion, signaling renewed industry confidence. Major pharma companies are actively acquiring promising biotech assets to reinforce their pipelines, address patent expiries, and expand into high-growth therapeutic areas.
With full-year 2025 M&A activity expected to cross USD 380-420 billion, the industry is firmly positioned for continued consolidation, innovation-led acquisitions, and strategic partnerships that shape the future landscape of global pharmaceutical development.
This report is also available in the following languages : Japanese (2025年第2四半期の製薬業界のM&A市場), Korean (2025년 2분기 제약 M&A 거래 시장), Chinese (2025年第二季度医药并购交易市场), French (Marché des fusions-acquisitions pharmaceutiques au deuxième trimestre 2025), German (Pharma-Fusionen und -Übernahmen im 2. Quartal 2025), and Italian (Operazioni di M&A nel settore farmaceutico nel secondo trimestre del 2025), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73660
Our More Reports:
Non-Fish Omega 3 Supplements Market
https://exactitudeconsultancy.com/reports/33451/non-fish-omega-3-supplements-market
Hand Lotion & Hand Cream Market
https://exactitudeconsultancy.com/reports/33758/hand-lotion-hand-cream-market
Pharma Parenteral Packaging Market
https://exactitudeconsultancy.com/reports/44514/pharma-parenteral-packaging-market
Pharma contract manufacturing (CMO) and Pharma contract packaging (CPO) Market
https://exactitudeconsultancy.com/reports/48113/pharma-contract-manufacturing-cmo-and-pharma-contract-packaging-cpo-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharma M&A Deals Market is Set to Experience a Revolutionary Growth here
News-ID: 4294792 • Views: …
More Releases from Exactitude Consultancy
Blockbuster Drugs on Patent Cliffs Market is expected to reach USD 148 billion b …
Market Overview
The Blockbuster Drugs on Patent Cliffs Market represents one of the most strategically significant transitions in the global pharmaceutical industry. A patent cliff occurs when exclusivity on a high-revenue drug expires, allowing generic or biosimilar competitors to enter the market, resulting in steep revenue declines for the original manufacturer and large opportunities for generic and biosimilar producers.
Between 2024 and 2030, over USD 258 billion worth of top-selling branded drugs…
HER2-Negative Breast Cancer Epidemiology Market is expected to reach USD 1.31 Mi …
Overview
HER2-negative breast cancer is the most common breast cancer subtype, accounting for approximately 70-75% of all breast cancer cases worldwide. It includes:
• Hormone Receptor Positive / HER2-Negative (HR+/HER2-): ~65% of all cases
• Triple-Negative Breast Cancer (TNBC): ~10-12% of all cases
The disease burden continues to grow due to rising screening rates, lifestyle risk factors, improved diagnostic technologies, and aging populations.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73664
In 2024, there are an…
CRO Activity and Intelligence Market is expected to reach USD 178.4 billion by 2 …
Market Overview
The CRO (Contract Research Organization) Activity and Intelligence Market covers all outsourced preclinical, clinical, regulatory, and post-approval research services conducted for pharmaceutical, biotechnology, medical device, and diagnostics companies. CROs have become a central strategic partner for drug developers, offering specialized capabilities, global infrastructure, and integrated scientific intelligence.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73662
In 2024, the market is valued at USD 91.5 billion, fueled by rising R&D…
Frozen Shoulder Syndrome Clinical Market Is projected to reach USD 4.12 billion …
Market Overview
The Frozen Shoulder Syndrome Clinical Market includes all diagnostic, therapeutic, and rehabilitative services used for the management of adhesive capsulitis-a painful, progressive shoulder condition characterized by stiffness, restricted mobility, and chronic inflammation of the joint capsule.
In 2024, the global market is valued at USD 2.48 billion, driven by increasing incidence of musculoskeletal disorders, rising geriatric population, and growing demand for physical therapy, corticosteroid injections, and minimally invasive procedures.
Download Full…
More Releases for M&A
industrials m&a,m&a project management,corporate finance mergers and acquisition …
Mergers and acquisitions (M&A) in the industrial sector refer to the process of one company acquiring another company or assets in the manufacturing, construction, and engineering industries. The industrial sector is characterized by a diverse range of businesses, including heavy machinery, aerospace, and defense, chemicals, and engineering services.
https://upworkservice.com/
China M&A advisory
E-mail:nolan@pandacuads.com
The industrial sector is characterized by a high level of consolidation, with companies looking to acquire other companies to gain access…
m&a company,m&a integration,cross border merger,m&a due diligence,m&a strategy,m …
Mergers and acquisitions (M&A) are a common way for companies to grow and diversify their business operations. The process of merging or acquiring another company can be complex and time-consuming, but when executed successfully, it can bring significant benefits to the acquiring company, such as access to new markets, technologies, and customers.
https://upworkservice.com
China M&A advisory
E-mail:nolan@pandacuads.com
When it comes to successful M&A, the key is to ensure that the two companies are a…
private equity m&a,international mergers and acquisitions,technology m&a,m&a pro …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. In the M&A process, there are two main parties involved: the buyer and the seller. One type of buyer that is becoming increasingly prevalent in the M&A landscape is private equity firms.
https://upworkservice.com/
China M&A advisory
E-mail:nolan@pandacuads.com
Private equity firms are investment firms that raise capital from institutional investors and high net…
buy side m&a,global m&a,bank mergers and acquisitions,m&a advisory firms,success …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. In the M&A process, there are two main parties involved: the buyer and the seller. The term "buy side" refers to the party that is acquiring the target company. In contrast, the "sell side" refers to the party that is being acquired.
https://upworkservice.com/
China M&A advisory
E-mail:nolan@pandacuads.com
The buy side M&A process…
due diligence in mergers and acquisitions,recent m&a deals 2023,m&a management,m …
Due diligence is an investigation process that companies undertake prior to a merger or acquisition (M&A) in order to assess the target company's financial and operational condition. The goal of due diligence is to identify any potential risks or opportunities that may impact the value of the acquisition and to ensure that the deal is in the best interest of the acquiring company. Due diligence is a critical step in…
m&a valuation,corporate mergers,m&a business,merger integration,sell side m&a pr …
Mergers and acquisitions (M&A) are a common strategy for companies looking to expand their operations, enter new markets, or acquire new technologies. One crucial aspect of the M&A process is the valuation of the target company. Valuation is the process of determining the fair value of a company, and it is an essential step in the M&A process because it helps companies to determine the terms of the acquisition, such…
